GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimerix Inc (STU:CXF) » Definitions » EV-to-FCF

Chimerix (STU:CXF) EV-to-FCF : -1.92 (As of Dec. 14, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Chimerix EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Chimerix's Enterprise Value is €123.87 Mil. Chimerix's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was €-64.51 Mil. Therefore, Chimerix's EV-to-FCF for today is -1.92.

The historical rank and industry rank for Chimerix's EV-to-FCF or its related term are showing as below:

STU:CXF' s EV-to-FCF Range Over the Past 10 Years
Min: -33.95   Med: -0.83   Max: 2.5
Current: -1.83

During the past 13 years, the highest EV-to-FCF of Chimerix was 2.50. The lowest was -33.95. And the median was -0.83.

STU:CXF's EV-to-FCF is ranked worse than
100% of 387 companies
in the Biotechnology industry
Industry Median: 8.7 vs STU:CXF: -1.83

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-14), Chimerix's stock price is €2.795. Chimerix's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.871. Therefore, Chimerix's PE Ratio (TTM) for today is At Loss.


Chimerix EV-to-FCF Historical Data

The historical data trend for Chimerix's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimerix EV-to-FCF Chart

Chimerix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.16 -6.30 -4.86 1.10 1.39

Chimerix Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.44 1.39 0.98 1.01 0.74

Competitive Comparison of Chimerix's EV-to-FCF

For the Biotechnology subindustry, Chimerix's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chimerix's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimerix's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Chimerix's EV-to-FCF falls into.



Chimerix EV-to-FCF Calculation

Chimerix's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=123.868/-64.514
=-1.92

Chimerix's current Enterprise Value is €123.87 Mil.
Chimerix's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-64.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chimerix  (STU:CXF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Chimerix's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.795/-0.871
=At Loss

Chimerix's share price for today is €2.795.
Chimerix's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.871.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Chimerix EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Chimerix's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Chimerix Business Description

Traded in Other Exchanges
Address
2505 Meridian Parkway, Suite 100, Durham, NC, USA, 27713
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.

Chimerix Headlines

No Headlines